LONDON MARKET OPEN: Glaxo To Co-Develop Covid Vaccine; Vodafone Rises
Wed, 3rd Feb 2021 08:47
(Alliance News) - Stock prices in London opened higher on Wednesday driven by progress over a US stimulus deal and on tackling the coronavirus pandemic.
The FTSE 100 index was up 52.26 points, or 0.8%, at 6,568.91. The mid-cap FTSE 250 index was up 163.89 points, or 0.8%, at 20,854.23. The AIM All-Share index was up 0.5% at 1,194.91.
The Cboe UK 100 index was up 0.8% at 653.35. The Cboe 250 was up 0.8% at 18,407.31 and the Cboe Small Companies was flat at 12,230.54.
In mainland Europe, the CAC 40 in Paris was up 0.8% while the DAX 30 in Frankfurt was up 1.4%.
UK drugmaker GlaxoSmithKline and German biopharmaceutical company CureVac announced a new EUR150 million collaboration to jointly develop next-generation mRNA vaccines for Covid-19, with the potential for a multi-valent approach to address multiple emerging variants in one vaccine.
Cannabis Global Increases Stake in Cannabis Manufacturer and Distributor Natural Plant Extract saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Cannabis Global, Inc.: Cannabis Global Increases Stake in Cannabis Manufacturer and Distributor Natural Plant Extract
LOS ANGELES, CA / ACCESSWIRE / February 2, 2021 / Cannabis Global, Inc. (OTC PINK:CBGL), an innovation-oriented company investing in and growing operations in disruptive areas of the cannabis and hemp-related industries, today announces it has increased its ownership stake in Natural Plant Extract of California, Inc. ( NPE ), which operates a licensed cannabis manufacturing and distribution business operation in Lynwood, California. NPE owns a Type 7 California Manufacturing License as well as a California Distribution license. Under the terms of the agreement, which closed on January 27, 2021, the Company is purchasing an additional (18.8%) of Natural Plant Extract s outstanding capital stock, bringing its full ownership position to approximately 37.6%. In exchange for the 18.8% ownership, the Company will issue approximately 11.4 million restricted shares to the se
Published: Feb 01, 2021
FINTEPLA offers a new treatment option for patients in Germany with Dravet syndrome, a rare, devastating, infant-onset epilepsy marked by frequent seizures, medical emergencies, and developmental impairments
FINTEPLA was approved by the European Commission in December 2020 based on data from two Phase 3 studies demonstrating it safely and significantly reduced convulsive seizure frequency for Dravet syndrome patients whose seizures were not adequately controlled on their existing medications
EMERYVILLE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE)
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that FINTEPLA
® (fenfluramine) oral solution is now available in Germany for the treatment of seizures associated with Dravet syndrome in patients aged two years and older, as an add-on therapy to existing anti-epileptic medications. Dravet syndrome is a rare, lifelong epilepsy that begins in infancy
Advertisement
Australian investment legend David Paradice has seen a lot of things in his distinguished funds management career. But nothing like the online frenzy that led to an incredible surge in shares of the obscure US retailer GameStop last week. âItâs been crazy to watch, itâs also been very interesting,â Mr Paradice told
The Age and
The Sydney Morning Herald. âIt really is madness.â
As this masthead revealed last week, Paradiceâs funds management firm Paradice Investment Management missed out on a potential $1 billion windfall after selling shares in GameStop just before a day trader revolt led to an incredible surge in the stock.